PharmaMar updates on PM1183 including trade name

16 June 2017

Spanish drugmaker PharmaMar (MC: PHM) says that PM1183 (lurbinectedin), its third molecule of marine origin and analogue of Yondelis (trabectedin), will receive the trade name of Zepsyre.

Zepsyre is currently undergoing development for the treatment of solid tumors. This promising agent is currently in final stage for platinum-resistant ovarian cancer and small cell lung cancer.

Both the European Medicines Agency and the Food and Drug Administration, as regulatory agencies, require the trade name to be unique and is part of the evaluation and approval process before marketing the product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK